› 7cgw

X-ray diffraction
3.2Å resolution

Complex structure of PD-1 and tislelizumab Fab

Released:
DOI: 10.2210/pdb7cgw/pdb
PDB entry 7cgw coloured by chain, front view.
PDB entry 7cgw coloured by chain, side view.
PDB entry 7cgw coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, Li Y, Zhang T, Zhang Y, Cui X, Li Z, Song X, Li K, Liu M, Liu Y
OpenAccess logo FEBS Open Bio 11 782-792 (2021)
PMID: 33527708

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-556644 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
Heavy chain of tislelizumab Fab Chains: A, H
Molecule details ›
Chains: A, H
Length: 228 amino acids
Theoretical weight: 24.48 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Light chain of tislelizumab Fab Chains: B, L
Molecule details ›
Chains: B, L
Length: 214 amino acids
Theoretical weight: 23.55 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Programmed cell death protein 1 Chains: C, P
Molecule details ›
Chains: C, P
Length: 151 amino acids
Theoretical weight: 16.98 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
UniProt:
  • Canonical: Q15116 (Residues: 25-169; Coverage: 55%)
Gene names: PD1, PDCD1
Sequence domains: Immunoglobulin V-set domain

Ligands and Environments

1 bound ligand:
Ligand NAG 7 x NAG
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SSRF BEAMLINE BL17U1
Spacegroup: C2221
Unit cell:
a: 142.638Å b: 145.572Å c: 175.549Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.22 0.218 0.254
Expression system: Homo sapiens

Quick links

Citations

5 review citations

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang et al. (2022)
4 more

3 mentions without citation

Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
Hong et al. (2021)
2 more